Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15479660 | 0.84 | MCL1 (0.41) | MCL1GAAHTTLMNAKMT2A | |
| SCHEMBL18858943 | 0.81 | CYP2D6 (0.41) | GAAHTTLMNAKMT2ANPC1 | |
| SCHEMBL22819443 | 0.81 | MCL1 (0.39) | MCL1GAAHTTLMNAFAAH | |
| SCHEMBL16750157 | 0.81 | LMNA (0.38) | MCL1GAAHTTLMNAKMT2A | |
| SCHEMBL25623226 | 0.78 | POLB (0.41) | GAAHTTKMT2ATDP1MEN1 | |
| SCHEMBL2603166 | 0.77 | KMT2A (0.33) | GAAHTTKMT2ANPC1MEN1 | |
| SCHEMBL19984231 | 0.77 | MCL1 (0.39) | MCL1FAAHKMT2AMEN1 | |
| SCHEMBL20849997 | 0.75 | MEN1 (0.52) | KMT2AMEN1 | |
| SCHEMBL1829003 | 0.75 | — | — | |
| SCHEMBL22822406 | 0.75 | PAOX (0.45) | LMNAFAAHKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095503-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | DUKE UNIVERSITY (US) | 2017-04-06 | — | — | US | disclosed |
| US-9468650-B2 | Inhibition of endosomal toll-like receptor activation | DUKE UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160250165-A1 | Method of Modulating the Activity of a Nucleic Acid Molecule | DUKE UNIVERSITY (US) | 2016-09-01 | — | — | US | disclosed |
| US-9340591-B2 | Method of modulating the activity of a nucleic acid molecule | DUKE UNIVERSITY (US) | 2016-05-17 | — | — | US | disclosed |
| US-20120245340-A1 | NOVEL ARTIFICIAL FLUORESCENT BASES | TAGCYX BIOTECHNOLOGIES (JP) | 2012-09-27 | — | — | US | disclosed |
| US-20120183564-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | DUKE UNIVERSITY | 2012-07-19 | — | — | US | disclosed |
| US-20100184822-A1 | Method of modulating the activity of a nucleic acid molecule | DUKE UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095503-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | TLR3, TLR9, TLR1 | MCL1 3758/4885GAA 318/4885HTT 3541/4885 |
| US-20120183564-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | TLR3, TLR9, TLR1 | MCL1 3758/4885GAA 318/4885HTT 3541/4885 |
| US-20120245340-A1 | NOVEL ARTIFICIAL FLUORESCENT BASES | NUDT1, NT5C3B, NSUN2 | MCL1 2075/4885GAA 1010/4885HTT 2201/4885 |
| US-20100184822-A1 | Method of modulating the activity of a nucleic acid molecule | NSUN2, POLRMT, POLM | MCL1 514/4885GAA 533/4885HTT 433/4885 |
| US-20160250165-A1 | Method of Modulating the Activity of a Nucleic Acid Molecule | NSUN2, POLRMT, POLM | MCL1 514/4885GAA 533/4885HTT 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.